M
96.22
0.10 (0.10%)
| Penutupan Terdahulu | 96.12 |
| Buka | 96.11 |
| Jumlah Dagangan | 1,424,406 |
| Purata Dagangan (3B) | 2,433,117 |
| Modal Pasaran | 7,298,015,232 |
| Harga / Jualan (P/S) | 120.74 |
| Harga / Buku (P/B) | 9.41 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Operasi (TTM) | -285.94% |
| EPS Cair (TTM) | -4.16 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 235.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.65% |
| Nisbah Semasa (MRQ) | 5.86 |
| Aliran Tunai Operasi (OCF TTM) | -237.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -112.40 M |
| Pulangan Atas Aset (ROA TTM) | -30.61% |
| Pulangan Atas Ekuiti (ROE TTM) | -58.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Merus N.V. | Bercampur | Menaik |
AISkor Stockmoo
-0.7
| Konsensus Penganalisis | 0.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.70 |
|
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 2.33% |
| % Dimiliki oleh Institusi | 99.34% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 97.00 (Leerink Partners, 0.81%) | Pegang |
| 97.00 (Canaccord Genuity, 0.81%) | Pegang | |
| 97.00 (Wells Fargo, 0.81%) | Pegang | |
| 97.00 (UBS, 0.81%) | Pegang | |
| 97.00 (LifeSci Capital, 0.81%) | Pegang | |
| 97.00 (Barclays, 0.81%) | Pegang | |
| 97.00 (HC Wainwright & Co., 0.81%) | Pegang | |
| 97.00 (Guggenheim, 0.81%) | Pegang | |
| 97.00 (Citigroup, 0.81%) | Pegang | |
| 97.00 (Truist Securities, 0.81%) | Pegang | |
| Median | 97.00 (0.81%) | |
| Rendah | 96.00 (Needham, -0.23%) | Pegang |
| Purata | 96.91 (0.72%) | |
| Jumlah | 11 Pegang | |
| Harga Purata @ Panggilan | 94.03 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Leerink Partners | 06 Oct 2025 | 97.00 (0.81%) | Pegang | 94.27 |
| Barclays | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| 17 Sep 2025 | 112.00 (16.40%) | Beli | 68.18 | |
| Canaccord Genuity | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| Guggenheim | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| HC Wainwright & Co. | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| LifeSci Capital | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| UBS | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| Wells Fargo | 30 Sep 2025 | 97.00 (0.81%) | Pegang | 94.15 |
| 29 Sep 2025 | 97.00 (0.81%) | Pegang | 93.67 | |
| Citigroup | 29 Sep 2025 | 97.00 (0.81%) | Pegang | 93.67 |
| Needham | 29 Sep 2025 | 96.00 (-0.23%) | Pegang | 93.67 |
| Truist Securities | 29 Sep 2025 | 97.00 (0.81%) | Pegang | 93.67 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LUNDBERG SVEN ANTE | 96.02 | 96.02 | -115,305 | -11,071,586 |
| SHUMAN HARRY | - | 96.02 | -8,300 | -796,966 |
| Jumlah Keseluruhan Kuantiti Bersih | -123,605 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -11,868,552 | |||
| Purata Pembelian Keseluruhan ($) | 96.02 | |||
| Purata Jualan Keseluruhan ($) | 96.02 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SHUMAN HARRY | Pegawai | 25 Nov 2025 | Jual (-) | 8,300 | 96.02 | 796,966 |
| SHUMAN HARRY | Pegawai | 25 Nov 2025 | Pelaksanaan pilihan | 8,300 | - | - |
| LUNDBERG SVEN ANTE | Pegawai | 25 Nov 2025 | Dibuang (-) | 30,297 | 96.02 | 2,909,118 |
| LUNDBERG SVEN ANTE | Pegawai | 25 Nov 2025 | Dibuang (-) | 125,460 | 96.02 | 12,046,669 |
| LUNDBERG SVEN ANTE | Pegawai | 25 Nov 2025 | Diperolehi (+) | 40,452 | 96.02 | 3,884,201 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |